JP2020505045A - ロングレンジ配列決定のためのバーコードを付けられたdna - Google Patents
ロングレンジ配列決定のためのバーコードを付けられたdna Download PDFInfo
- Publication number
- JP2020505045A JP2020505045A JP2019540460A JP2019540460A JP2020505045A JP 2020505045 A JP2020505045 A JP 2020505045A JP 2019540460 A JP2019540460 A JP 2019540460A JP 2019540460 A JP2019540460 A JP 2019540460A JP 2020505045 A JP2020505045 A JP 2020505045A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- barcode
- sequence
- dna
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012163 sequencing technique Methods 0.000 title claims description 84
- 238000000034 method Methods 0.000 claims abstract description 75
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 73
- 230000000295 complement effect Effects 0.000 claims abstract description 60
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 47
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 47
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 142
- 239000002773 nucleotide Substances 0.000 claims description 140
- 230000000977 initiatory effect Effects 0.000 claims description 76
- 230000003321 amplification Effects 0.000 claims description 63
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 63
- 230000015572 biosynthetic process Effects 0.000 claims description 45
- 238000003786 synthesis reaction Methods 0.000 claims description 45
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 32
- 235000019395 ammonium persulphate Nutrition 0.000 claims description 32
- 238000000137 annealing Methods 0.000 claims description 32
- 238000000261 appearance potential spectroscopy Methods 0.000 claims description 32
- 108091034117 Oligonucleotide Proteins 0.000 claims description 30
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- 238000009396 hybridization Methods 0.000 claims description 12
- 229960002685 biotin Drugs 0.000 claims description 11
- 239000011616 biotin Substances 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 235000020958 biotin Nutrition 0.000 claims description 9
- 238000002372 labelling Methods 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 230000037452 priming Effects 0.000 claims description 7
- 239000005546 dideoxynucleotide Substances 0.000 claims description 6
- 238000012412 chemical coupling Methods 0.000 claims description 3
- 238000010586 diagram Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 210
- 108020004635 Complementary DNA Proteins 0.000 description 65
- 238000010804 cDNA synthesis Methods 0.000 description 65
- 239000002299 complementary DNA Substances 0.000 description 65
- 238000006243 chemical reaction Methods 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 32
- 102000053602 DNA Human genes 0.000 description 29
- 210000000349 chromosome Anatomy 0.000 description 22
- 239000000523 sample Substances 0.000 description 19
- 239000012634 fragment Substances 0.000 description 17
- 102000054766 genetic haplotypes Human genes 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102100034343 Integrase Human genes 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 125000006850 spacer group Chemical group 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 8
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 108020004682 Single-Stranded DNA Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000005945 translocation Effects 0.000 description 6
- 108090001008 Avidin Proteins 0.000 description 5
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 5
- 238000005562 fading Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 238000007400 DNA extraction Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000007614 genetic variation Effects 0.000 description 4
- 238000012165 high-throughput sequencing Methods 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 230000008775 paternal effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 2
- 241000713838 Avian myeloblastosis virus Species 0.000 description 2
- 208000016718 Chromosome Inversion Diseases 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 108050009160 DNA polymerase 1 Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000028782 Hereditary disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108010043595 captavidin Proteins 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- -1 cells Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007841 sequencing by ligation Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 238000012070 whole genome sequencing analysis Methods 0.000 description 2
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical group [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 208000036086 Chromosome Duplication Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000007845 assembly PCR Methods 0.000 description 1
- 108700021042 biotin binding protein Proteins 0.000 description 1
- 102000043871 biotin binding protein Human genes 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019689 luncheon sausage Nutrition 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012176 true single molecule sequencing Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/161—Modifications characterised by incorporating target specific and non-target specific sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2533/00—Reactions characterised by the enzymatic reaction principle used
- C12Q2533/10—Reactions characterised by the enzymatic reaction principle used the purpose being to increase the length of an oligonucleotide strand
- C12Q2533/101—Primer extension
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
- C12Q2535/122—Massive parallel sequencing
Abstract
Description
本開示のDNAにバーコードを付ける方法が、図1A〜Cにおいて図説されている。断片化されたDNA試料、例えば断片化されたゲノム、エキソームまたは他のタイプのDNAが、(すなわち一本鎖DNAを作り出すために)融解または変性させられ、後の精製のために3’末端においてビオチンで末端標識される(図1A)。この工程は、おおよそ30分間で完了されることができる。
Claims (14)
- 核酸配列アセンブリを促進するための方法であって、該方法が、以下の工程:
a)一本鎖鋳型核酸を含む核酸試料を提供すること;
b)それぞれの鋳型核酸に1以上のバーコード開始プライマーをプライミングさせてアニーリングした核酸会合体を作製すること、ここでそれぞれのバーコード開始プライマーは3’鋳型ハイブリダイゼーション部分および5’バーコード開始部分を含む;
c)ポリメラーゼ伸長を実施して相補鎖を作製すること、ここで該相補鎖は該鋳型核酸にアニーリングしたままである;
d)2ラウンド以上のオリゴヌクレオチドコード単位“アッセイ可能なポリマーサブユニット”(APS)をカップリングさせるスプリットプール合成を実施して、該バーコード領域、該プライマー領域および該標的核酸に相補的な標的特異的領域を含む該相補鎖のそれぞれにおけるオリゴヌクレオチドバーコード配列を組み立てること;
e)該バーコードを付けられた相補鎖を配列決定すること;ならびに
f)該バーコード配列を用いて、同じ鋳型核酸から生じた該バーコードを付けられた相補鎖を同定し、そして該バーコードを付けられた相補鎖の該標的特異的領域から該鋳型核酸配列を組み立てること;
を含む、前記方法。 - さらに工程(b)の前に該一本鎖鋳型核酸を該3’末端において親和性タグで末端標識することを含む、請求項1に記載の方法。
- 該親和性タグがビオチンである、請求項1または2に記載の方法。
- 該3’バーコード開始部分が、ランダム配列を含む、先行する請求項のいずれか1項に記載の方法。
- 工程c)における該ポリメラーゼ伸長が、ジデオキシヌクレオチドを含む、先行する請求項のいずれか1項に記載の方法。
- 該APSが約7ヌクレオチドの定められた配列を含むエラーチェック用サブコード(SC)を含み、それが該試料中の他のSCと少なくとも3ヌクレオチド異なる、先行する請求項のいずれか1項に記載の方法。
- それぞれのAPSがランダム配列を含む、先行する請求項のいずれか1項に記載の方法。
- さらに同じ鋳型核酸から生じたバーコードを付けられた相補鎖を計数し、それにより該鋳型核酸の最初のコピー数を検出する工程を含む、先行する請求項のいずれかに記載の方法。
- 該APSが、スプリント分子へのアニーリングによりカップリングされる、先行する請求項のいずれか1項に記載の方法。
- 該APSが、クリック化学を用いてカップリングされる先行する請求項のいずれか1項に記載の方法。
- バーコード開始プライマーのセット、1以上のポリメラーゼ、ヌクレオチド、ジデオキシヌクレオチド、アッセイ可能なポリマーサブユニット(APS)のセット、1以上の鋳型分子(スプリント)、ライゲーション試薬、クリック化学カップリング試薬、増幅プライマーおよび配列決定プライマーからなる構成要素を含むキット。
- 該バーコード開始プライマーが、ランダムプライマー配列領域を含む、請求項11に記載のキット。
- 該APSのセットが、2〜20の独特のAPSを含む、請求項11または12に記載のキット。
- 該APSがオリゴヌクレオチドである、請求項11〜13のいずれか1項に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762451354P | 2017-01-27 | 2017-01-27 | |
US62/451,354 | 2017-01-27 | ||
PCT/EP2018/051909 WO2018138237A1 (en) | 2017-01-27 | 2018-01-26 | Barcoded dna for long range sequencing |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020505045A true JP2020505045A (ja) | 2020-02-20 |
JP7033602B2 JP7033602B2 (ja) | 2022-03-10 |
Family
ID=61094499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019540460A Active JP7033602B2 (ja) | 2017-01-27 | 2018-01-26 | ロングレンジ配列決定のためのバーコードを付けられたdna |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200010893A1 (ja) |
EP (1) | EP3574112B1 (ja) |
JP (1) | JP7033602B2 (ja) |
CN (1) | CN110291207A (ja) |
WO (1) | WO2018138237A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11639928B2 (en) | 2018-02-22 | 2023-05-02 | 10X Genomics, Inc. | Methods and systems for characterizing analytes from individual cells or cell populations |
SG11202008080RA (en) * | 2018-02-22 | 2020-09-29 | 10X Genomics Inc | Ligation mediated analysis of nucleic acids |
JP7332694B2 (ja) * | 2018-12-04 | 2023-08-23 | エフ. ホフマン-ラ ロシュ アーゲー | 細胞標的の空間指向性量子バーコード化 |
WO2020254672A1 (en) | 2019-06-19 | 2020-12-24 | Therycell Gmbh | Spatial characterisation of target structures in a sample |
CN110702831B (zh) * | 2019-11-18 | 2020-06-16 | 天津汉科生物科技有限公司 | 一种超高效液相色谱-串联质谱检测血清睾酮激素的试剂盒 |
WO2022182682A1 (en) | 2021-02-23 | 2022-09-01 | 10X Genomics, Inc. | Probe-based analysis of nucleic acids and proteins |
EP4308723A1 (en) | 2021-03-15 | 2024-01-24 | F. Hoffmann-La Roche AG | Targeted next-generation sequencing via anchored primer extension |
EP4314337A1 (en) | 2021-04-01 | 2024-02-07 | F. Hoffmann-La Roche AG | Immune cell counting of sars-cov-2 patients based on immune repertoire sequencing |
WO2024076908A1 (en) * | 2022-10-03 | 2024-04-11 | 10X Genomics, Inc. | Compositions and methods for analyzing genomic insertion sites of exogenous nucleic acids |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014513916A (ja) * | 2011-01-31 | 2014-06-19 | アプライズ バイオ, インコーポレイテッド | 細胞において複数のエピトープを同定する方法 |
WO2016100976A2 (en) * | 2014-12-19 | 2016-06-23 | Apprise Bio, Inc. | Methods for identifying multiple epitopes in selected sub-populations of cells |
WO2016160844A2 (en) * | 2015-03-30 | 2016-10-06 | Cellular Research, Inc. | Methods and compositions for combinatorial barcoding |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268564B2 (en) | 2007-09-26 | 2012-09-18 | President And Fellows Of Harvard College | Methods and applications for stitched DNA barcodes |
US20150376609A1 (en) | 2014-06-26 | 2015-12-31 | 10X Genomics, Inc. | Methods of Analyzing Nucleic Acids from Individual Cells or Cell Populations |
CA2900481A1 (en) | 2013-02-08 | 2014-08-14 | 10X Genomics, Inc. | Polynucleotide barcode generation |
KR102436171B1 (ko) | 2013-06-27 | 2022-08-24 | 10엑스 제노믹스, 인크. | 샘플 처리를 위한 조성물 및 방법 |
US20150376700A1 (en) | 2014-06-26 | 2015-12-31 | 10X Genomics, Inc. | Analysis of nucleic acid sequences |
CN107208144B (zh) * | 2014-11-21 | 2021-06-08 | 纳米线科技公司 | 无酶且无扩增的测序 |
US20180073073A1 (en) * | 2015-03-18 | 2018-03-15 | Cellular Research, Inc. | Methods and compositions for labeling targets and haplotype phasing |
-
2018
- 2018-01-26 CN CN201880008693.5A patent/CN110291207A/zh active Pending
- 2018-01-26 EP EP18702220.7A patent/EP3574112B1/en active Active
- 2018-01-26 WO PCT/EP2018/051909 patent/WO2018138237A1/en unknown
- 2018-01-26 JP JP2019540460A patent/JP7033602B2/ja active Active
-
2019
- 2019-07-22 US US16/518,794 patent/US20200010893A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014513916A (ja) * | 2011-01-31 | 2014-06-19 | アプライズ バイオ, インコーポレイテッド | 細胞において複数のエピトープを同定する方法 |
WO2016100976A2 (en) * | 2014-12-19 | 2016-06-23 | Apprise Bio, Inc. | Methods for identifying multiple epitopes in selected sub-populations of cells |
WO2016160844A2 (en) * | 2015-03-30 | 2016-10-06 | Cellular Research, Inc. | Methods and compositions for combinatorial barcoding |
Non-Patent Citations (1)
Title |
---|
EVAN Z. MACOSKO ET AL.: "Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets", CELL, vol. 161, no. 5, JPN6021044957, 2015, pages 1202 - 1214, ISSN: 0004637918 * |
Also Published As
Publication number | Publication date |
---|---|
CN110291207A (zh) | 2019-09-27 |
EP3574112A1 (en) | 2019-12-04 |
US20200010893A1 (en) | 2020-01-09 |
EP3574112B1 (en) | 2023-01-11 |
JP7033602B2 (ja) | 2022-03-10 |
WO2018138237A1 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7033602B2 (ja) | ロングレンジ配列決定のためのバーコードを付けられたdna | |
US20210071171A1 (en) | Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation | |
EP2914745B1 (en) | Barcoding nucleic acids | |
EP3555305B1 (en) | Method for increasing throughput of single molecule sequencing by concatenating short dna fragments | |
JP2020522243A (ja) | 核酸のマルチプレックス末端タギング増幅 | |
WO2016022833A1 (en) | Digital measurements from targeted sequencing | |
JP6608384B2 (ja) | コピー数が保持されるrna分析法 | |
CN108138228B (zh) | 用于下一代测序的高分子量dna样品追踪标签 | |
US20230056763A1 (en) | Methods of targeted sequencing | |
WO2013074833A1 (en) | Capture probe and assay for analysis of fragmented nucleic acids | |
US20240117343A1 (en) | Methods and compositions for preparing nucleic acid sequencing libraries | |
US20200299764A1 (en) | System and method for transposase-mediated amplicon sequencing | |
CN117015603A (zh) | 使用基于转座子的技术与用于误差校正的独特分子标识符制备定向标签化测序文库的方法 | |
WO2005010184A1 (ja) | 変異の検出方法 | |
WO2005038026A1 (ja) | 変異のタイピング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210108 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220224 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220228 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7033602 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |